SCHEMBL169994

SCHEMBL169994

CCCCOCCn1nc(C(=O)OC)cc1C(=O)O

nearest known ligand 0.43

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
SMPD1 P17405 3/20 0.39
RARB P10826 2/20 0.38
ALPL P05186 1/20 0.36
RARA P10276 1/20 0.36
PLA2G2A P14555 3/20 0.36
TSHR P16473 2/20 0.36
RECQL P46063 1/20 0.36
TP53 P04637 1/20 0.35
GAA P10253 1/20 0.35
HTT P42858 1/20 0.35
HRH3 Q9Y5N1 1/20 0.35
CNR1 P21554 2/20 0.34
CNR2 P34972 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL171958 0.92 SMPD1 (0.41) SMPD1ALPLTSHRRECQLTP53
SCHEMBL20661082 0.81 GRN (0.45)
SCHEMBL20419549 0.80 AURKA (0.40) TSHRGAA
SCHEMBL12532886 0.79 MAPKAPK2 (0.40)
SCHEMBL171962 0.76 CNR2 (0.38) SMPD1CNR1CNR2
SCHEMBL20661034 0.75 HPGD (0.44)
SCHEMBL22151650 0.72 KDM4E (0.41) TSHRGAAHTT
SCHEMBL20660724 0.72 KDM4E (0.35) GAA
SCHEMBL1267336 0.72 KDM4E (0.50)
SCHEMBL22151409 0.72 KDM4E (0.40) TSHRGAAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9650371-B2 Sulfur-containing heterocyclic derivative having beta secretase inhibitory activity SHIONOGI & CO., LTD. (JP) 2017-05-16 US disclosed
US-20160326158-A1 SULFUR-CONTAINING HETEROCYCLIC DERIVATIVE HAVING BETA SECRETASE INHIBITORY ACTIVITY SHIONOGI & CO (JP) 2016-11-10 US disclosed
US-20120071475-A1 UREA DERIVATIVES HAVING PI3K-INHIBITING ACTIVITY SHIONOGI & CO., LTD. (JP) 2012-03-22 US disclosed
EP-2426135-A1 UREA DERIVATIVE HAVING PI3K INHIBITORY ACTIVITY Shionogi&Co., Ltd. (JP) 2012-03-07 EP disclosed
US-20110230472-A1 RING-FUSED AZOLE DERIVATIVE HAVING PI3K-INHIBITING ACTIVITY SHIONOGI & CO., LTD. (JP) 2011-09-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160326158-A1 SULFUR-CONTAINING HETEROCYCLIC DERIVATIVE HAVING BETA SECRETASE INHIBITORY ACTIVITY BACE1, BACE2, APP SMPD1 1683/4885RARB 2627/4885ALPL 3814/4885
US-20110230472-A1 RING-FUSED AZOLE DERIVATIVE HAVING PI3K-INHIBITING ACTIVITY PIK3R5, PIK3R4, PIK3R1 SMPD1 2687/4885RARB 1381/4885ALPL 706/4885
US-20120071475-A1 UREA DERIVATIVES HAVING PI3K-INHIBITING ACTIVITY MTOR, STAT3, SLC14A1 SMPD1 909/4885RARB 2792/4885ALPL 698/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.